CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB

CervoMed Inc.

Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.
FDA alignment on design of planned Phase 3 trial of neflamapimod for dementia with Lewy bodies; global pivotal trial initiation targeted H2 2026.
Phase 2b RewinD-LB 32-week data showed 64% risk reduction in clinically significant worsening on CDR-SB (p<0.001) in DLB patients with low AD co-pathology.
R&D expenses $6.0M (up $0.9M YoY) primarily due to increased personnel and CMC activities; G&A $2.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.